Allianz Asset Management
ALXN

Allianz Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Allianz Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,000
Closed -$2.02M – 2486
2020
Q2 		$2.02M Buy
+18,000
New +$1.91M ﹤0.01% 1603
2020
Q1 		– Sell
-7,300
Closed -$789K – 2821
2019
Q4 		$789K Buy
7,300
+2,100
+40% +$225K ﹤0.01% 2283
2019
Q3 		$509K Buy
5,200
+2,300
+79% +$259K ﹤0.01% 2370
2019
Q2 		$380K Buy
2,900
+1,100
+61% +$142K ﹤0.01% 2433
2019
Q1 		$243K Sell
1,800
-1,600
-47% -$199K ﹤0.01% 2534
2018
Q4 		$331K Sell
3,400
-3,200
-48% -$378K ﹤0.01% 2393
2018
Q3 		$917K Sell
6,600
-1,800
-21% -$226K ﹤0.01% 2249
2018
Q2 		$1.04M Buy
8,400
+800
+11% +$93.5K ﹤0.01% 2223
2018
Q1 		$847K Sell
7,600
-26,000
-77% -$3.11M ﹤0.01% 2256
2017
Q4 		$4.02M Buy
33,600
+1,700
+5% +$207K ﹤0.01% 1730
2017
Q3 		$4.47M Buy
31,900
+9,500
+42% +$1.29M ﹤0.01% 1672
2017
Q2 		$2.73M Sell
22,400
-8,600
-28% -$1M ﹤0.01% 1880
2017
Q1 		$3.76M Sell
31,000
-20,300
-40% -$2.62M ﹤0.01% 1746
2016
Q4 		$6.28M Buy
51,300
+19,300
+60% +$2.36M 0.01% 1559
2016
Q3 		$3.92M Buy
32,000
+8,900
+39% +$1.15M ﹤0.01% 1717
2016
Q2 		$2.7M Buy
23,100
+10,500
+83% +$1.49M ﹤0.01% 1786
2016
Q1 		$1.75M Buy
12,600
+1,400
+13% +$206K ﹤0.01% 1879
2015
Q4 		$2.14M Buy
11,200
+6,100
+120% +$1.07M ﹤0.01% 1683
2015
Q3 		$798K Sell
5,100
-7,600
-60% -$1.39M ﹤0.01% 1924
2015
Q2 		$2.3M Buy
12,700
+5,200
+69% +$897K ﹤0.01% 1662
2015
Q1 		$1.3M Sell
7,500
-2,200
-23% -$398K ﹤0.01% 1701
2014
Q4 		$1.79M Buy
9,700
+6,600
+213% +$1.22M ﹤0.01% 1599
2014
Q3 		$514K Buy
+3,100
New +$509K ﹤0.01% 1889

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Allianz Asset Management's ALXN Position: Q3 2021 in Review

Allianz Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 117,856 shares — an estimated $21.7M sold.

Allianz Asset Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $166M in Q1 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Allianz Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Allianz Asset Management sold 117,856 Alexion Pharmaceuticals shares in Q3 2021, an estimated $21.7M.
  • Allianz Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Allianz Asset Management's Alexion Pharmaceuticals position peaked at $166M in Q1 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Allianz Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.